HLA B Leader in Psoriatic Arthritis
Official title: HLA B Leader in Patients With Psoriatic Arthritis
Run by Centre Hospitalier Universitaire, Amiens · NCT07718815 · Data updated 2026-11-12
This study tests whether the HLA B leader gene is more common in people with psoriatic arthritis than in healthy individuals.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 658 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens, Picardie) |
| Status | Recruiting |
| Started | May 6, 2025 |
| Main results expected | September 2026 |
| Study ends | September 2026 |
| Registry record updated | July 22, 2026 |
| Trial ID | NCT07718815 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with psoriatic arthritis followed at CHU Amiens-Picardie who meet CASPAR criteria, and healthy adults over 18 with no inflammatory or autoimmune diseases.
✕Probably not a fit
Healthy individuals without psoriatic arthritis may not benefit from the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will compare the presence of the HLA B leader gene between adults with psoriatic arthritis and healthy controls. The study uses a blood test to detect the gene variant and involves participants from CHU Amiens-Picardie. It is observational in nature and does not involve a treatment; instead, it looks for genetic differences that may be linked to disease. Eligibility focuses on adults over 18 who are affiliated with a social security scheme, with patients meeting CASPAR criteria for PsA. Languages include French, and participation requires informed consent and cohort linkage at Amiens.
Why it matters
Potential benefit: If the gene difference is found, it could improve understanding of PsA biology and potentially guide future research on personalized approaches.
How similar studies have gone: Genetic association studies have explored HLA-related risk in inflammatory diseases, but this specific HLA B leader association in PsA is not yet established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * For the "Patient" group: * Patient over 18 years of age * Patient affiliated to a social security scheme * Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie. * For the "control" group: * Individuals over 18 years of age * Individual affiliated to a social security scheme * Individual having agreed to participate in the study * Individuals with no inflammatory or autoimmune diseases Exclusion Criteria: * Patient or control not understanding French * Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort. * Patient or control objecting to participation in the study
Where it's running
-
CHU Amiens Picardie
Amiens, Picardie, France Recruiting
Study contacts
- Study coordinator: Vincent Goeb, Pr
- Email: Goeb.vincent@chu-amiens.fr
- Phone: 33+3.22.08.83.71
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TaVNS for Psoriatic Arthritis in Adults
This study tests whether non-invasive taVNS can help reduce disease activity and improve pain and quality of life in adults with psoriatic arthritis.
-
TQH3906 capsules for active psoriatic arthritis in adults
This trial tests whether TQH3906 capsules help people with active psoriatic arthritis more than a placebo over 12 weeks.
-
Picankibart for people with active psoriatic arthritis
This trial tests whether subcutaneous picankibart can improve joint and skin symptoms in adults with active psoriatic arthritis who have not had enough benefit from NSAIDs or non-biologic DMARDs.
-
Bimekizumab by IV infusion versus subcutaneous injection for adults with psoriatic arthritis or axial spondyloarthritis
This trial tests whether bimekizumab given by intravenous (IV) infusion behaves the same in the body as the usual subcutaneous injection in adults with psoriatic arthritis or axial spondyloarthritis.
-
Continued daily zasocitinib treatment for adults with psoriatic arthritis
This extension will try daily zasocitinib in adults with psoriatic arthritis who completed a year of earlier treatment to see how well it works and how safe it is over about two years.
-
Creating Health online course for people with rheumatological conditions
This project will test whether an online course about diet and self-care helps adults with rheumatoid arthritis, Sjogren's syndrome, lupus, mixed connective tissue disease, or psoriatic arthritis reduce fatigue and improve quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.